Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Stockspawkon Jun 15, 2019 11:47am

173 Views

Post# 29828888

RE:RE:RE:Must Read article - Antibe

Nice post. Always interested to hear your thoughts. I too think there will be a bidding war. I mean this has the potential to make and pharma company billions of dollars just on 346 alone. I am really hoping that 2019 is the year that we get past the $1.00 mark and stay there. The potential for this company is limitless and I hope to hear some good news in the near future.

Bullboard Posts

The investment impact of the U.S. 25% tariff on Canadian imports